Telangiectasis: Clinical Trials

13 trials for Telangiectasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 13
Phase 25Completed 5

Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors
Phase 1CompletedBayer562019-09-302024-04-02
MRA With Feraheme in HHT
Feraheme MRI/MRA - Hereditary Hemorrhagic Telangiectasia
Phase 1CompletedUniversity of California, Los Angeles102016-11-012019-01-25
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
Pomalidomide - Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Phase 1CompletedThe Cleveland Clinic92015-01-272020-07-15
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
bevacuzimab spray - Telangiectasia, Hereditary Hemorrhagic
Phase 1 / Phase 2CompletedUniversity Hospital, Caen202014-12-152026-07-30
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Topical timolol maleate, placebo saline drops - Hereditary Hemorrhagic Telangiectasia
Phase 1 / Phase 2CompletedUnity Health Toronto52013-05-012023-09-21
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
Bevacizumab - Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
Phase 1CompletedHospices Civils de Lyon422011-10-012021-10-19
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Sclerotherapy, Standard Treatment - Epistaxis, Hereditary Hemorrhagic Telangiectasia
Phase 1 / Phase 2CompletedUniversity of Minnesota182011-02-012019-11-01
Combination Therapy for the Treatment of Rosacea
calcium dobesilate, pulsed dye laser - Erythematotelangiectatic Rosacea
Phase 1CompletedEllen Marmur62009-07-012019-06-17
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia
Phase 1 / Phase 2CompletedManhattan Eye, Ear & Throat Hospital182007-05-012012-10-25
Effects of PRK 124 Lotion in Acne Rosacea
PRK 124 - Acne Rosacea
Phase 1 / Phase 2CompletedUniversity of California, Irvine242007-04-012014-01-17
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
Ranibizumab - Telangiectasia
Phase 1CompletedNational Eye Institute (NEI)52007-03-272017-07-02
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
Ranibizumab - Telangiectasia
Phase 1CompletedNational Eye Institute (NEI)52007-03-272017-07-02
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
Ranibizumab - Telangiectasia
Phase 1CompletedJohns Hopkins University102006-09-012012-11-14

Narrower conditions

Telangiectasia, Hereditary Hemorrhagic (6)  ·  Epistaxis (2)  ·  Idiopathic Juxtafoveal Retinal Telangiectasia (2)  ·  Papilledema (2)  ·  Rosacea (2)  ·  Acne Vulgaris (1)  ·  Ataxia Telangiectasia (1)  ·  Erythema (1)  ·  Flushing (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Myopia, Degenerative (1)  ·  Polypoidal Choroidal Vasculopathy (1)  ·  Pseudoxanthoma Elasticum (1)  ·  Retinal Telangiectasis (1)

Broader conditions

Cardiovascular Diseases (13)  ·  Vascular Diseases (13)  ·  Congenital Abnormalities (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Hematologic Diseases (7)  ·  Hemic and Lymphatic Diseases (7)  ·  Hemorrhagic Disorders (7)  ·  Hemostatic Disorders (7)  ·  Cardiovascular Abnormalities (6)  ·  Vascular Malformations (5)  ·  Nervous System Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Eye Diseases (3)  ·  Pathologic Processes (3)

Interventions

Ranibizumab (4)  ·  BAY 1895344 (1)  ·  Bevacizumab (1)  ·  Calcium Dobesilate (1)  ·  Ferrosoferric Oxide (1)  ·  Lasers, Dye (1)  ·  Sclerotherapy (1)  ·  Sodium Tetradecyl Sulfate (1)  ·  Timolol (1)  ·  pembrolizumab (1)  ·  pomalidomide (1)  ·  pyratine 6 (1)

Sponsors

National Eye Institute (NEI) (2)  ·  Bayer (1)  ·  Ellen Marmur (1)  ·  Hospices Civils de Lyon (1)  ·  Johns Hopkins University (1)  ·  Manhattan Eye, Ear & Throat Hospital (1)  ·  The Cleveland Clinic (1)  ·  Unity Health Toronto (1)  ·  University Hospital, Caen (1)  ·  University of California, Irvine (1)  ·  University of California, Los Angeles (1)  ·  University of Minnesota (1)

Countries

United States (10)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Ellen Marmur, MD (1)  ·  Gerald D Weinstein, MD (1)  ·  Holly Boyer, MD (1)  ·  Justin McWilliams, MD (1)  ·  Keith McCrae, MD (1)  ·  Lawrence A. Yannuzzi, MD (1)  ·  Marie E Faughnan, MD MSc FRCPC (1)  ·  Neil M. Bressler, MD (1)

Results publications

PMID 24481211, PMID 39510938

NIH funding

2018 (1), U54NS065705 (1)